← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #1639 OF 1,916 MOST-CITED

Determination of lot numbers and supplies

FDA cited this observation 6 times across 6 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Biologics6
BY FISCAL YEAR
FY20241
FY20191
FY20181
FY20171
FY20162

How FDA worded it — real examples

Appropriate records are not available to determine the lot numbers of supplies used for specific units of the final product.

Hemarus LLC · Lauderhill, Florida · Biologics · 2024-04-30

Appropriate records are not available to determine the lot numbers of supplies used for specific units of the final product.

Department of Defense - Air Force · Dayton, Ohio · Biologics · 2019-09-26

Appropriate records are not available to determine the lot numbers of supplies used for specific units of the final product.

A Plus Phlebotomy Services · Huntingdon Valley, Pennsylvania · Biologics · 2018-03-14

Appropriate records are not available to determine the lot numbers of supplies used for specific units of the final product.

Reston Hospital Center · Reston, Virginia · Biologics · 2016-12-09

Appropriate records are not available to determine the lot numbers of supplies used for specific units of the final product.

Medical Home Health Options dba The Plasma Source · New Hope, Pennsylvania · Biologics · 2016-07-12

Appropriate records are not available to determine the lot numbers of supplies and reagents used for specific units of the final product.

Elmhurst Hospital Center · Elmhurst, New York · Biologics · 2016-06-24

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Biologics industry

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →